Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
HyHyperinsulism due to UCP2 deficiency (HIUCP2) is a form of diazoxide-sensitive diffuse hyperinsulinism (DHI) characterized by hypoglycemic episodes from the neonatal period, a good clinical response to diazoxide and a probable transient nature of the disease with spontaneous resolution.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hyperinsulinism due to UCP2 deficiency.
4 publications have been identified in PubMed for hyperinsulinism due to UCP2 deficiency. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (25%), and Basic Science / Preclinical (25%).
Zaczek A (2024). [PMID: 38517641](https://pubmed.ncbi.nlm.nih.gov/38517641/). *Geroscience*. [Basic Science / Preclinical]
Nesci S (2024). [PMID: 38927514](https://pubmed.ncbi.nlm.nih.gov/38927514/). *Biomedicines*. [Review / Meta-Analysis]
Telehuz D (2024). [PMID: 38952388](https://pubmed.ncbi.nlm.nih.gov/38952388/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Wang K (2024). [PMID: 39707176](https://pubmed.ncbi.nlm.nih.gov/39707176/). *Mol Med*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center